Knowledge and awareness of biosimilars among oncology patients in Colorado, USA

Papers of special note have been highlighted as: • of interest

References

• 1. US FDA. Biosimilar product information. (2019). www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580432.htm
  Google Scholar
• 2. Gordon N, Stemmer SM, Greenberg D, Goldstein DA. Trajectories of injectable cancer drug costs after launch in the United States. J. Clin. Oncol. 36(4), 319–325 (2018).
  Medline CASGoogle Scholar
• 3. Waller J, Sullivan E, Piercy J, Black CM, Kachroo S. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Prefer. Adherence 11, 519–530 (2017). • The German study demonstrating the importance of informed decision-making to improve acceptance of biosimilars among patient with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis.
  MedlineGoogle Scholar
• 4. Greer JA, Jacobs JM, El-Jawahri A et al. Role of patient coping strategies in understanding the effects of early palliative care on quality of life and mood. J. Clin. Oncol. 36(1), 53–60 (2018).
  Medline CASGoogle Scholar
• 5. Ismailov RM, Khasanova ZD. Biosimilar knowledge among oncology/hematology team members in Colorado, USA: an educational initiative and follow-up survey. BioDrugs 32(5), 499–506 (2018). • The first study aimed to improve the oncology/hematology team member’s knowledge of biosimilars in Colorado.
  Medline CASGoogle Scholar
• 6. Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer. Adherence 10, 937–948 (2016). • An international survey of participants from several countries demonstrating knowledge gaps concerning such important topics as safety, efficacy and access to biosimilars.
  MedlineGoogle Scholar
• 7. Silverberg M, Weizberg M, Murano T, Smith JL, Burkhardt JC, Santen SA. What is the prevalence and success of remediation of emergency medicine residents? West J. Emerg. Med. 16(6), 839–844 (2015).
  MedlineGoogle Scholar
• 8. Gimenez Verotti CC, De Miranda Torrinhas RS, Pires Corona L, Waitzberg DL. Design of quality indicators for oral nutritional therapy. Nutr. Hosp. 31(6), 2692–2695 (2015).
  MedlineGoogle Scholar
• 9. Pearson D, Bond MC, Kegg J et al. Evaluation of social media use by emergency medicine residents and faculty. West J. Emerg. Med. 16(5), 715–720 (2015).
  MedlineGoogle Scholar
• 10. Van Overbeeke E, De Beleyr B, De Hoon J, Westhovens R, Huys I. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs 31(5), 447–459 (2017).
  MedlineGoogle Scholar
• 11. Annual report: cancer mortality continues decline. J. Nucl. Med. 59(7), 11N (2018).
  Google Scholar
• 12. Goldstein DA, Clark J, Tu Y et al. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget 8(42), 71548–71555 (2017).
  MedlineGoogle Scholar
• 13. Charles C, Whelan T, Gafni A. What do we mean by partnership in making decisions about treatment? BMJ 319(7212), 780–782 (1999).
  Medline CASGoogle Scholar
• 14. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353(5), 487–497 (2005).
  Medline CASGoogle Scholar
• 15. Peyrin-Biroulet L, Lonnfors S, Roblin X, Danese S, Avedano L. Patient perspectives on biosimilars: a survey by the European Federation of Crohn's and Ulcerative Colitis Associations. J. Crohns Colitis 11(1), 128–133 (2017).
  MedlineGoogle Scholar